The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics.
Retrovirally mediated functional genomics enables identification of physiologically relevant cellular therapeutic targets. Unique properties of retroviruses make them ideal tools for the introduction of large and diverse libraries of potential genetic effectors to a variety of cell types. The identification and recovery of intracellular library elements responsible for altered disease responses establishes a direct basis for pharmaceutical development. Recent innovations in retroviral infection efficiency and expression control have broadened application of the methodology to include libraries of mutagenized cDNAs, peptides and ribozyme genetic effectors.
Lorens
J B
JB
Rigel, Inc., 240 East Grand Avenue, South San Francisco, CA 94080, USA. jblorens@rigel.com
Sousa
C
C
Bennett
M K
MK
Molineaux
S M
SM
Payan
D G
DG
D000818:Animals; D018076:DNA, Complementary / Q000378:metabolism; D004345:Drug Industry / Q000379:methods*; D015723:Gene Library; D018014:Gene Transfer Techniques; D017930:Genes, Reporter; D016678:Genome; D006801:Humans; D051379:Mice; D008954:Models, Biological; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D016337:RNA, Catalytic / Q000737:chemistry; D012190:Retroviridae / Q000235:genetics*
D018076:DNA, Complementary; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic